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Background. Clinical improvement in inflammatory bowel disease (IBD) treated with methotrexate and 6-mercaptopurine (6-
MP) is associated with a decrease in pro-inflammatory cytokines. This has been presumed to indicate the mechanism of action
of methotrexate and 6-MP. Although controversial, there are increasingly compelling data that Mycobacterium avium
subspecies paratuberculosis (MAP) may be an etiological agent in some or all of IBD. We hypothesized that the clinical efficacy
of methotrexate and 6-MP in IBD may be to simply inhibit the growth of MAP. Methodology. The effect on MAP growth
kinetics by methotrexate and 6-MP were evaluated in cell culture of two strains each of MAP and M. avium using a radiometric
(
14CO2 BACTECH) detection system that quantifies mycobacterial growth as arbitrary ‘‘growth index units’’ (GI). Efficacy data
are presented as ‘‘percent decrease in cumulative GI’’ (% 2DcGI). Principal Findings. The positive control antibiotic
(clarithromycin) has $85% 2DcGI at a concentration of 0.5 mg/ml. The negative control (ampicillin) has minimal inhibition at
64 mg/ml. MAP ATCC 19698 shows $80% 2DcGI for both agents by 4 mg/ml. With the other three isolates, although more
effective than ampicillin, 6-MP is consistently less effective than methotrexate. Conclusions. We show that methotrexate and
6-MP inhibit MAP growth in vitro. Each of the four isolates manifests different % 2DcGI. These data are compatible with the
hypothesis that the clinical improvement in patients with IBD treated with methotrexate and 6-MP could be due to treating
a MAP infection. The decrease in pro-inflammatory cytokines, thought to be the primary mechanism of action, may simply be
a normal, secondary, physiological response. We conclude that henceforth, in clinical studies that evaluate the effect of anti-
MAP agents in IBD, the use of methotrexate and 6-MP should be excluded from any control groups.
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INTRODUCTION
Mycobacterium avium subspecies paratuberculosis (MAP) causes Johne’s
disease [1] in cattle worldwide. Johne’s disease is clinically
evocative of inflammatory bowel disease (IBD) in humans. The
possibility that MAP may be zoonotic [2] is the subject of much
interest [3] [4] (& see [5] for review.) Since first seeing our MAP
RNA data [6], we have posited in private, in peer reviewing
manuscripts [3,7,8], and at professional congresses that MAP is
the primary and most culpable, potential etiological agent for
some or all of IBD.
In the therapy of IBD, (and several other inflammatory diseases)
both methotrexate and 6-MP are used because of empirical
efficacy, even though their precise mechanism of action is
unknown. [9] [10,11] Their use is attended by clinical improve-
ment that is associated with a decrease in pro-inflammatory
cytokines. Consequently, prevailing medical dogma posits that the
mode of action of methotrexate and 6-MP, is to decrease the
production of pro-inflammatory cytokines, and as a consequence
the ‘‘inflammatory’’ response that is the consequence of these
cytokines is diminished. This results in a clinical improvement in
diseases that are conventionally conceptualized as being primarily
‘‘inflammatory.’’
Both methotrexate and 6-MP interfere with DNA replication.
Methotrexate acts by inhibiting dihydrofolate reductase, folate
generation and the consequent production of adenine.[12] The
mechanism of action of 6-MP is to substitute for guanine in DNA
replication.[12] Because prokaryotes must synthesize their own
folic acid, they should be more susceptible to folate inhibition than
eukaryotes. It is noteworthy that there are two distinct doses in
human clinical use for both methotrexate and 6-MP. Each agent
has a ‘‘high’’ dose, (used in to treat reticuloendothelial malignan-
cies [13,14]) and a ‘‘low’’ dose (used to treat ‘‘inflammatory’’
diseases. [15] [16])
We hypothesized that the clinically relevant mechanism of
action of ‘‘low’’ dose methotrexate and 6-MP in the therapy of
IBD, may, in whole or part, be due to the inhibition of MAP
growth. If this hypothesis is correct, the decrease in the pro-
inflammatory cytokines, heretofore considered the primary
mechanism of action of these two agents, could simply represent
a secondary phenomenon. The observed decrease in pro-
inflammatory cytokines could be ascribed to the treatment of the
instigating MAP infection. To evaluate this hypothesis we have
studied the effect of methotrexate and 6-MP on MAP and other
M. avium isolates in culture. The effect of methotrexate has been
evaluated on E. coli [17], 6-MP on Salmonella typhimurium [18] and
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first time that these two agents have been evaluated for their effect
on MAP.
METHODS
This study was approved by the Research & Development
Committee at the VAMC Bronx NY (0720-06-038) and was
conducted under the Institutional Radioactive Materials Permit
(#31-00636-07).
Culture
In this study, we used four well-characterized strains of mycobac-
teria. Two were MAP, a bovine isolate, ATCC 19698 (ATCC
Rockville MD) and ‘‘Dominic’’ a human isolate from an individual
with Crohn’s disease (originally isolated by R. Chiodini [20].) The
M. Avium subspecies avium strains (hereinafter called M. avium) were
ATCC 25291 (veterinary source) and M. avium 101 [21]. Primary
cultures were performed in Middlebrook 7H9 medium supple-
mented 9:1 with ADC (Both Difco. Detroit MI). All media for
MAP (liquid and agar plates) were supplemented with 1 mg/ml
Mycobactin J (Allied Monitor. Fayette MO.)
The detergent Tween 80 (recommended to prevent mycobac-
terial clumping) renders clinically resistant strains of MAP
inappropriately susceptible to antimicrobials in cell culture. [22]
Accordingly in our experiments, Tween 80 was not used. To
minimize mycobacterial clumping, one ml of the log phase
bacterial culture (,GI of 500) in 7H12 medium in the BACTEC
vial was passaged $20 times through a 25 gauge needle [23] on
a one ml syringe (Becton-Dickerson Franklin Lakes NJ), added to
five ml 7H9 medium supplemented with Mycobactin J, vortexed
and left standing at ambient temperature for 30 minutes.
Subsequently, only the upper three of the six ml. were used for
inoculations. The number of CFU’s inoculated was determined by
plating serial dilutions of the inoculum onto 7H10 plates (Difco)
supplemented for MAP with Mycobactin J (1 mg/ml) and counted
when colonies were easily visualized (two to six weeks). At the
time of passage, additional aliquots were plated onto blood agar
plates to ensure that inocula were not contaminated with non-
mycobacterial organisms.
To confirm the identity of the species studied, DNA was
obtained from the isolates (High Pure Template Prep. Kit Roche
Diagnostics Indianapolis IN), PCR amplified using primers for IS
900 (MAP) [24]and IS 901/2 [25] (M. avium & specific subspecies
including silveticum) as described. [6] Amplicon sizes were deter-
mined using 1% agarose gel electrophoresis. DNA sequence
analysis was performed commercially, (Genewiz North Brunswick
NJ) with sequence comparison performed using BLAST (NLM).
The positive antibiotic control clarithromycin (gift of Abbott
Chicago IL) was dissolved in methanol. The negative control
Table 1. Differences in growth kinetics and consequent length of experiment for each isolate.
..................................................................................................................................................
MAP M. avium
ATCC 19698 (Fig 1) ATCC 19698 (Fig 2) Dominic (Fig 2) ATCC 25291 (Fig 2) 101 (Fig 2)
GI at harvest 526 523 548 669 267
Harvested # CFU’s/ml 8.1610
5 8.2610
5 6.3610
5 9.1610
6 1.2610
6
# CFU’s Inoculated 20,250 20,500 15,750 910 120
Days to reach GI ‘‘999’’ 12 13 17 7 5
doi:10.1371/journal.pone.0000161.t001
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Figure 1. Shown is a bar graph of the cumulative GI data evaluating MAP ATCC 19698. Each drug dilution was studied in duplicate. Error bars are SD.
There are three control inoculations, labeled on the abscissa as ‘‘0, 00 & 000. The left hand ‘‘0’’ had an equal number of CFU’s as in each drug studied.
‘‘00’’ = 10 & ‘‘000’’ = 100 fold dilutions. In each control the maximum concentration of diluent used for each agent (methanol for Clarithromycin,
water for ampicillin and NaOH for methotrexate and 6-MP) was added. Clarithromycin is most effective and ampicillin is the least effective at
decreasing MAP growth. Both methotrexate and 6-MP are as effective as clarithromycin in MAP %2DcGI at a dose of 4 mg/ml.
doi:10.1371/journal.pone.0000161.g001
‘‘Immunomodulators’’ & MAP
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in water. Methotrexate and 6-mercaptopurine (both Sigma) were
dissolved in NaOH at a maximal final concentration of 50 mM
(Sigma). Control inocula were performed using the maximum
concentration of each diluent. Agents were tested in serial dilutions
from a minimum of 0.05 mg/ml to a maximum of 64 mg/ml (see
individual Figures). Aliquots of chemicals being evaluated were
prediluted, stored at 280uC, thawed, used once and discarded.
Data are presented as cumulative growth index (cGI) units6SD
(when necessary, see individual figures). The effect (or lack thereof)
of each agent is presented as the percent decrease in cGI units (%
2DcGI), compared to the control cGI of that isolate in the diluent
(e.g. methanol or NaOH) that was used for the specific chemical
being evaluated. cGI data for each experiment is presented until
the day prior to any GI reading exceeding the assay limit of ‘‘999’’
(Table 1). Raw data was archived onto Excel, and the cumulative
results transferred to Prism (Graphpad, San Diego CA) for final
graphing.
RESULTS
Bacterial quantification must be performed retrospectively.
Accordingly, for experimental reproducibility, bacterial passage
and harvesting were performed when the GI was ,500. Quantifi-
cation show that the CFU’s of the M. avium isolates are approxi-
mately 10 fold higher (,1610
7 CFU’s/ml), compared to MAP
(,1610
6 CFU’s/ml) (Table 1). Because of the difference in
growth kinetics, M. avium CFU #’s inoculated were $10 fold
lower than MAP (Table 1).
Both of our MAP isolates (ATCC 19698 & Dominic) were
Mycobactin J dependant (data not presented), were IS 900 positive
and had $99% homology with the GenBank accession
NC_002944 of MAP (data not presented). M. avium ATCC 25
291 was positive for IS 902 and M. avium 101 was negative for both
(Data not presented).
In our pivotal study (Figure 1) the positive control antibiotic,
clarithromycin exhibits $86% 2DcGI at the lowest concentration
evaluated (0.5 mg/ml). The negative control antibiotic (the
Figure 2. A composite graph of the four bacterial strains studied. ‘‘0’’ is diluent control with an equal CFU inoculum and ‘‘00’’ is a 1:10 dilution of the
water control inoculum. Drug concentrations are indicated on the abscissa. For each isolate, drug dose was studied in singlicate. For all four bacteria,
clarithromycin has achieved maximal inhibition by 1 mg/ml. For MAP ATCC 19698, replicating data presented in Figure 1, both methotrexate and
6-MP %2DGI is the same as for clarithromycin by 4 mg/ml. Note that with the other MAP isolate (Dominic) and both M. avium isolates, methotrexate
is more effective at a lower dose than is 6-MP. The lower cumulative GI (seen on the ordinate) for the M. avium isolates is ascribable to their more
rapid growth and earlier reaching the off scale BACTEC GI values of ‘‘999.’’
doi:10.1371/journal.pone.0000161.g002
‘‘Immunomodulators’’ & MAP
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32 mg/ml. In contrast, 6-MP has an initial $43% 2DcGI starting
at 1 mg/ml increasing to $84% 2DcGI at 4 mg/ml. Methotrexate
has 40% 2DcGI inhibition at 2 mg /ml and $75% 2DcGI at
4 mg/ml. (Figure 1.)
We additionally evaluated the effect of methotrexate and 6-MP
against two MAP and two M. avium isolates (Figure 2). In these
studies, the MAP 19698 results replicate the data presented in
Figure 1 showing ,80% 2DcGI inhibition at 4 mg/ml for both 6-
MP and clarithromycin. In contrast, MAP Dominic shows less
susceptibility to 6-MP (41% 2DcGI at 4 mg/ml) compared to
MAP 19698 (84%2DGI at 4 mg/ml). Both M. avium isolates show
less susceptibility to 6-MP than to methotrexate (Figure 2). The
diluent control inoculum for the M. avium ATCC 25291 appears to
exhibit completely inhibited growth (Figure 2: Bottom left graph,
left hand column.) However, over the following two days this
methanol control entered log phase growth, whereas the vials at
every clarithromycin dose continued to show no evidence of
growth (data not presented.)
DISCUSSION
The efficacy of both methotrexate and 6-MP in the therapy of IBD
is uncontested. Prevailing dogma accepts that the decrease in
pro-inflammatory cytokines that attends their use is responsible
for their beneficial effect. In this study we show that both
methotrexate and 6-MP inhibit the growth kinetics of MAP. In the
event that IBD is eventually accepted as being due to a MAP
infection, our data are compatible with our hypothesis that
methotrexate and 6-MP may be impairing MAP growth. If so, the
decrease in pro-inflammatory cytokines could simply be an
appropriate physiological response to their antibiotic-like activity.
We additionally show that there is a variation in response of
the four different isolates to our tested agents. Three of the four
isolates are more sensitive to methotrexate than to 6-MP. These
observations need to be further evaluated in multiple isolates from
a variety of individuals and clinical settings where development of
MAP resistance may be responsible for a clinical deterioration. We
conclude that antibiotic susceptibility testing will probably be
indicated for putative MAP infections, just as they are for other
(myco) bacterial infections.
As is conventional with antibiotic susceptibility studies, we
compared agents on an equal weight basis. However, methotrex-
ate (MW 450) is a much larger molecule than 6-MP (MW 170)
with a molar ratio of ,3:1. Thus, in comparison to 6-MP on
a molar basis, methotrexate is an even more potent inhibitor of
growth than our data indicate. Additionally, a simple extrapola-
tion of our data to a comparison with conventional ‘‘antibiotics’’
therapy is difficult. The dosages of methotrexate and 6-MP in
clinical use have not been titrated according to standard antibiotic
conventions. Dosage has been individualized, influenced by such
factors as hematological toxicity and patient tolerance.
There is a remarkable discrepancy between the doses of
methotrexate and 6-MP, used to treat different diseases, that
merit discussion. Each agent has a ‘‘high’’ dose, (used in to treat
reticuloendothelial malignancies [13,14]) and a ‘‘low’’ dose (used
to treat ‘‘inflammatory’’ diseases. [15] [16]) For methotrexate the
antineoplastic dose may be 1500–5000 mg M
2 by IV infusion over
2–24 hours (for a 70 kg man this could equate to 7500 mg in
24 hours.)[26] In contrast, for IBD a typical dose is 25 mg PO or
IM weekly. We suggest that this 300-fold disparity may reflect the
difference between treating a eukaryotic reticuloendothelial
malignancy and a prokaryotic mycobacterial (specifically we
hypothesize in the case of IBD a MAP) infection.
Our data are compatible with the thesis, but do not conclusively
prove, that MAP may be zoonotic. Corroboration of our data will
be necessary and multiple additional studies, both basic and
clinical need to be performed. However, we suggest that, as
a consequence of our observations antecedent clinical studies that
have evaluated anti-MAP agents need to be reevaluated and that
henceforth such studies will need to exclude methotrexate and 6-
MP from ‘‘control’’ or placebo subjects.
Conclusions and recommendations
We show that both methotrexate, as well as 6-MP, interfere with
the growth of MAP, an organism that may be the etiological factor
for some, or all of IBD. Some of the implications of these
observations are discussed.
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